the potential is huge Mikee3003 wrote:Indeed CS additional TLT maintenace treatments will be investigated, just takes time to run through the trials.
I'm going to use Rituximab as an example (one of the top selling oncology drugs with annual sale of approximately $8.5 billion, it is also the world's first onclogy monoclonal antibody therapy). My own personal experience with maintenance treatments has been with Rituxamab for my battle with indolent lymphoma (FNHL). FNHL was the first cancer for which the FDA approved Rituximab use. Since it's initial approval in 1997, Rituximab has been through hundreds of various clinical trials, today there are still many trials studying Rituximab.....that's right, still doing trials 25 years after first being approved!
i've used the mAb as an example to hilight how early we are in the TLT story. If we have the success we are expecting with NMIBC we will no doubt be seeing many, many trials for many, many years.
All the Best
Mikee
Appreciate your example Mikee & wish you the best in your battle. You bring up a great point...if all goes well, this current trial will likely be the first of very many. I am hopeful TLT's ACT can be the WD-40 of cancer treatment...used alone, as an adjuvant/add-on, or as a combo treatment for many cancer indications...not to mention infections. Good luck & wish you well.